Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 3:26 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1489–1512 of 1,762 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Major Depressive Disorders Clear all

Conditions: Anhedonia, Major Depressive Disorder
Interventions: Placebo, NBI-1065846; Drug
Lead sponsor: Neurocrine Biosciences; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 93 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 22
States / cities: Birmingham, Alabama • Garden Grove, California • Lemon Grove, California + 19 more

Conditions: Major Depressive Disorder
Interventions: BMS-986511, Placebo; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 21
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Rogers, Arkansas + 18 more

Conditions: Major Depressive Disorder
Interventions: PNB01 fixed dose combination of pipamperone and citalopram, Citalopram, Pipamperone; Drug
Lead sponsor: PharmaNeuroBoost N.V.; Industry
Eligibility: 18 Years and older
Enrollment: 555 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 26
States / cities: Glendale, California • National City, California • Riverside, California + 22 more

Conditions: Major Depressive Disorder, Back Pain, Aged
Interventions: Duloxetine; Drug
Lead sponsor: University of Pittsburgh; Other
Eligibility: 60 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Major Depressive Disorder
Interventions: Not listed
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 65 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 5
States / cities: Farmington, Connecticut • Chicago, Illinois • Boston, Massachusetts + 2 more

Conditions: Alcohol Abuse, Schizophrenia, Bipolar Disorder, Major Depressive Disorder
Interventions: Contingency Management; Behavioral
Lead sponsor: University of Washington; Other
Eligibility: 18 Years to 65 Years
Enrollment: 123 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Depression
Interventions: Nimodipine, Placebo; Drug
Lead sponsor: University of Pittsburgh; Other
Eligibility: 50 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Major Depressive Episode, Borderline Personality Disorder, Suicide
Interventions: Intermittent Theta Burst Transcranial Magnetic Stimulation (Active), Intermittent Theta Burst Transcranial Magnetic Stimulation (Sham); Device
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 65 Years
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Major Depressive Disorder
Interventions: NMRA-335140, Placebo; Drug
Lead sponsor: Neumora Therapeutics, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 383 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 64
States / cities: Huntsville, Alabama • Phoenix, Arizona • Bentonville, Arkansas + 56 more

Conditions: Major Depressive Disorder
Interventions: VASOPRESSIN V1B RECEPTOR ANTAGONIST (SSR149415), Placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Major Depressive Disorder
Interventions: Cognitive Behavioral Therapy (CBT), Whole-Body Hyperthermia; Behavioral · Device
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 3
States / cities: San Francisco, California • Boston, Massachusetts • Cleveland, Ohio

Conditions: Major Depression
Interventions: Not listed
Lead sponsor: Steward St. Elizabeth's Medical Center of Boston, Inc.; Other
Eligibility: 18 Years to 60 Years
Enrollment: 160 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Late Life Treatment Resistant Depression, Depression - Major Depressive Disorder, Treatment Resistant Depression
Interventions: Aripiprazole Augmentation, Bupropion Augmentation; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 60 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 2
States / cities: St Louis, Missouri • Pittsburgh, Pennsylvania

Conditions: Depression - Major Depressive Disorder, Anxiety, PTSD - Post Traumatic Stress Disorder, Insomnia, Alcohol Use Disorder (AUD), Suicide Ideation
Interventions: Deaf CBT-TS; Behavioral
Lead sponsor: University of Rochester; Other
Eligibility: 18 Years and older
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Major Depressive Disorder
Interventions: agomelatine, placebo; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 508 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2006
U.S. locations: 42
States / cities: Scottsdale, Arizona • Little Rock, Arkansas • Cerritos, California + 38 more

Conditions: Bipolar I Depression
Interventions: Armodafinil, Placebo; Drug
Lead sponsor: Cephalon; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 257 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 42
States / cities: Birmingham, Alabama • Escondido, California • Lafayette, California + 35 more

Conditions: Autonomic Nervous System (ANS) Functioning and Mood State
Interventions: Not listed
Lead sponsor: University of Arizona; Other
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Depression
Interventions: Motivational interviewing, Treatment as usual; Behavioral
Lead sponsor: University of Medicine and Dentistry of New Jersey; Other
Eligibility: 18 Years to 65 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: New Brunswick, New Jersey

Conditions: Depression, Suicide
Interventions: Ketamine; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 65 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Depression
Interventions: Interpersonal Psychotherapy (IPT), Individual Psychotherapy; Behavioral
Lead sponsor: University of Rochester; Other
Eligibility: 18 Years and older · Female only
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2007
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Major Depression
Interventions: Psilocybin, modafinil, zolpidem, pimavanserin; Drug
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years to 70 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2031
U.S. locations: 4
States / cities: San Diego, California • San Francisco, California • Minneapolis, Minnesota + 1 more

Conditions: Major Depressive Disorder (MDD)
Interventions: No Intervention: Observational Cohort; Other
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Depression, Anxiety
Interventions: Not listed
Lead sponsor: Assurex Health Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 104 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Multiple Sclerosis, Spinal Cord Injury
Interventions: Motivational interviewing, Education; Behavioral
Lead sponsor: University of Washington; Other
Eligibility: 45 Years and older
Enrollment: 123 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: Seattle, Washington

Search by objective public record fields.

Study to Evaluate the Efficacy and Safety of Once-Weekly Oral NBI-1065846 in the Treatment of Anhedonia in MDD

A Study to Evaluate BMS-986511 in Adults With Major Depressive Disorder

Pipamperone/Citalopram (PNB01) Versus Citalopram (CIT) and Versus Pipamperone (PIP) in Major Depressive Disorder (MDD)

Duloxetine Treatment of Major Depression and Chronic Low Back Pain For Older Adults

Exploring a Potential Blood Test to Diagnose Major Depressive Disorder

Contingency Management of Alcohol Abuse in the Severely Mentally ILL

Effectiveness of Nimodipine Plus Antidepressant Medication in Treating Vascular Depression

Circuit-Based Approach to Suicide: Biomarkers, Predictors, and Novel Therapeutics

Study to Evaluate the Effects of Oral NMRA-335140 Versus Placebo in Participants With Major Depressive Disorder

Evaluation of the Potential Effects of SSR149415 on the Hypothalamic-pituitary-adrenal Axis in Outpatients With Major Depressive Disorder

Multi-site Feasibility of an Integrated Treatment for the Biology and Experience of Depression: The MULTIBED Study

Serum Markers as a Bioassay for Unipolar Depression

The BAARD Study : Evaluating a Computerized Approach to Treatment Selection in Older Adults With Treatment Resistant Depression.

Deaf CBT-TS to Reduce Suicide Risk

Efficacy, Safety and Tolerability of Agomelatine in the Treatment of Major Depressive Disorder

Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder

Effects of Barefoot Running vs. in Shoes on Physiology and Mood

Motivational Interviewing to Improve Medication Adherence Among Hispanic Adults With Depression

Ketamine for Depression and Suicide Risk

Comparison of Two Psychotherapy Treatments for Depressed Women With a History of Sexual Abuse

Psilocybin for Depression in Veterans

Longitudinal Assessment of Biomarkers Among Patients With MDD

Retrospective Analysis of Outcomes With a Pharmacogenomic Algorithm

Motivational Interviewing to Increase Physical Activity to Treat Depression in People Aging With MS or SCI